TY - JOUR T1 -特发性肺纤维化急性加重:国际调查,并呼吁协调摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.01760 -2019欧元六世- 55 - 4 SP - 1901760 AU - Kreuter如此说道,迈克尔盟,赶在马库斯AU -沃尔什,西蒙L.F.盟——Krisam Johannes盟,羽衣甘蓝,哈罗德·r . AU -乔杜里Nazia AU -ž,谢尔盖AU - Behr Jurgen AU - Calligaro,格里高利AU -科尔特大学,Tamera盟,Flaherty Kevin AU - Funke-Chambour曼非盟-科尔布,马丁盟——Kondoh Yasuhiro AU -马赫,Toby M. AU - Molina Molina, Maria AU - Morais, Antonio AU - Moor, Catharina C. AU - Morisset, Julie AU - Pereira, Carlos AU - Quadrelli, Silvia AU - Selman, Moises AU - Tzouvelekis, Argyrios AU - Valenzuela, Claudia AU - Vancheri, Carlo AU - vicen - zygmunt, Vanesa AU - Wälscher, Julia AU - Wuyts, Wim AU - Wijsenbeek, Marlies AU - Cottin, Vincent AU - Bendstrup，Elisabeth Y1 - 2020/04/01 UR - //www.qdcxjkg.com/content/55/4/1901760.abstract N2 -特发性肺纤维化急性加重(AE-IPF)是IPF的常见致命并发症。目前还没有专门针对AE-IPF管理的国际指南。这项国际调查的目的是评估AE-IPF预防、诊断和治疗策略的全球可变性。具有ILD专业知识的肺科医生被邀请参加由国际专家小组设计的调查。来自66个国家的509名肺科医生参与了调查。发现AE-IPF管理方法存在显著的地理差异。常见的预防措施包括抗纤维化药物和接种疫苗。诊断差异最明显的是使用Krebs von den Lungen-6和病毒检测，而高分辨率计算机断层扫描，脑钠肽和d -二聚体通常被应用。广泛使用高剂量类固醇(94%); the use of other immunosuppressant and treatment strategies is highly variable. Very few (4%) responders never use immunosuppression. Antifibrotic treatments are initiated during AE-IPF by 67%. Invasive ventilation or extracorporeal membrane oxygenation are mainly used as a bridge to transplantation. Most physicians educate patients comprehensively on the severity of AE-IPF (82%) and consider palliative care (64%).Approaches to the prevention, diagnosis and treatment of AE-IPF vary worldwide. Global trials and guidelines to improve the prognosis of AE-IPF are needed.Lack of focussed international guidelines for management of acute exacerbation of IPF results in global variability in prevention, diagnosis and treatment strategies. Global trials are urgently needed to inform international specific guidelines for AE-IPF. http://bit.ly/3a8FB5i ER -